Use these materials to raise awareness about new immunisation products to protect infants in early life from a top cause of severe respiratory infections in children.

Strengthening of nonpharmaceutical interventions changed the epidemic dynamics of pediatric infectious diseases, with a trend toward older hospitalized children.

Some children and young people (CYP) infected with SARS-COV-2 experience impairing symptoms post-infection, known as post-COVID-19 condition (PCC).

This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, next steps are outlined to minimise the delay.

From being a largely unknown pathogen, RSV is now almost a household word. New solutions, such as long-acting monoclonal antibodies and maternal vaccination, both recently recommended by WHO, could dramatically alter the RSV landscape.

Influenza is a common contagious respiratory virus that primarily causes respiratory tract infections.

Respiratory syncytial virus (RSV) is a leading cause of hospitalization among young children. Historically, American Indian and Alaska Native (AI/AN) children have experienced high rates of RSV-associated hospitalization.

This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTI) in a large primary care network in Spain.

Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.

Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children.

ESWI Summit 2024: Early Career Scientists They each delivered a presentation introducing themselves and their ongoing work on RSV, bringing innovative ideas and making clear calls for action.

Keynote Lecture by Simon Drysdale, St George's University Hospitals NHS Foundation Trust

Keynote Lecture by Stefan Gravenstein, Brown University

Keynote Lecture by Dexter Wiseman, Imperial College London

Live attenuated vaccines; NIRSE-GAL: Evaluation of the effectiveness and impact of Nirsevimab in Galicia; and Therapeutics

By Ab Osterhaus, Host of the ESWI Respiratory Virus Summit 2024

How to ensure/prepare for access to immunisation programmes

Conclusions by Peter Openshaw, Co-Chair of the the ESWI Respiratory Virus Summit 2024

Uptake of COVID-19 vaccines among pregnant individuals was hampered by safety concerns around potential risks to unborn children.

Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022.